Evidence map›Paper›PMID 38322198›Full record

ReviewHepatobiliary surgery and nutrition2024

Management of hepatocellular carcinoma recurrence after liver surgery and thermal ablations: state of the art and future perspectives.

Astrid Herrero, Cyprien Toubert, Jose Ursic Bedoya, Eric Assenat, Boris Guiu, Fabrizio Panaro, Thomas Bardol, Gianluca Cassese

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Hepatobiliary surgery and nutrition, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
31citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

31 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Sex disparity in liver cancer recurrence-from bench to bedside.Hepatobiliary surgery and nutrition · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Astrid HerreroDepartment of HPB Surgery and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
Cyprien ToubertDepartment of HPB Surgery and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
Jose Ursic BedoyaDepartment of Hepatology and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
Eric AssenatDepartment of Digestive Oncology, Saint Eloi Hospital, Montpellier University, Montpellier, France.
Boris GuiuDepartment of Radiology, Saint Eloi Hospital, Montpellier University, Montpellier, France.
Fabrizio PanaroDepartment of HPB Surgery and Liver Transplantation, Saint Eloi Hospital, Montpellier University, Montpellier, France.
Thomas BardolLaboratory of rare human Circulating Cells (LCCRH), University Medical Center of Montpellier, Montpellier, France.
Gianluca CasseseDivision of Minimally Invasive and Robotic HPB Surgery, Department of Clinical Medicine and Surgery, Federico II University Hospital, Naples, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the improvements in surgical and medical therapy for hepatocellular carcinoma (HCC), recurrence still represents a major issue. Up to 70% of patients can experience HCC recurrence after liver resection (LR), as well as 20% of them even after liver transplantation (LT). The patterns of recurrence are different according to both the time and the location. Similarly, the risk factors and the management can change not only according to these patterns, but also according to the underlying liver condition and to the first treatment performed. Deep knowledge of such correlation is fundamental, since prevention and effective management of recurrence are undoubtedly the most important strategies to improve the outcomes of HCC treatment. Without adjuvant therapy, maintaining very close monitoring during the first 2 years in order to diagnose curable recurrence and continue this monitoring beyond 5 years because late recurrences exist, remains our only possibility today. Surgery represents the cornerstone treatment for HCC, including both LT and LR. However, new interesting therapeutic opportunities are coming from immunotherapy that has shown encouraging results also in the adjuvant setting. In such a complex and evolutionary scenario, the aim of this review is to summarize current strategies for the management of HCC recurrence, focusing on the different possible scenarios, as well as on future perspectives.

Indexed as

hepatocellular carcinoma managementHepatocellular carcinoma recurrenceliver surgeryliver transplantationsurvival after recurrencethermal ablation (TA)

Identifiers

PMID38322198
PMCPMC10839736

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.